Copy/Paste the key inputs from the product brochure, per guidance from Marketing.
The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira, Janssen’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia); and IL-17 inhibitors (Novartis’s Cosentyx and Eli Lilly’s Taltz). The TNF-α inhibitors are the most widely prescribed biologics for AxSpA that is refractory to nonsteroidal anti-inflammatory drugs (NSAIDs). However, these agents face a competitive threat, both from the launch of cost-effective biosimilars and from the growing IL-17 class. In 2019, the FDA approved Cimzia for nonradiographic (nr)-AxSpA, marking the first FDA approval for this subpopulation, followed by both IL-17 inhibitors in June 2020. The recent approval of novel oral targeted therapies—JAK inhibitors (Pfizer’s Xeljanz and AbbVie’s Rinvoq)—for ankylosing spondylitis (AS) and the impending entry of an additional IL-17 inhibitor (UCB’s bimekizumab) will further shift market dynamics.
Geographies: United States, EU5, Japan
Primary research: Approximately 30 country-specific interviews with thought-leading rheumatologists; supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalent cases of AxSpA by country; AS and nr-AxSpA subpopulations.
Forecast: 10-year, annualized, drug-level sales and patient share of key AxSpA therapies through 2031, segmented by brands / generics and epidemiological subpopulations
Emerging therapies: Phase III: 1 drug; Phase II: 2 drugs
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.